INCYTE - Dusseldorf Stock Exchang (ICY DU) stock market data APIs
€84.8073
0(0%)
as of December 23, 2025
Try our APIs with
free plan!
INCYTE - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ICY.DU.
Prev. Close
84.8073
Open
84.9435
High
85.5424
Low
84.2322
52 wk Range
48.52-93.58
Market Cap
12 792 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INCYTE - Dusseldorf Stock Exchang data using free add-ons & libraries
Get INCYTE - Dusseldorf Stock Exchang Fundamental Data
INCYTE - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INCYTE - Dusseldorf Stock Exchang News
New
Is It Too Late To Consider Incyte After A 45% Rally In 2025?
If you are wondering whether Incyte at around $100 a share is still good value or if the easy gains are behind it, you are not alone. This is exactly the question we are going to unpack. The stock is ...
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan
In recent days, Incyte announced that the European Commission and Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) and Zynyz (retifanlimab) in new combination regimens f...
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
Incyte (INCY) shares soared 5.5% in the last trading session to close at $102.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
TOKYO, December 22, 2025--(BUSINESS WIRE)--Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
